Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioDlink International Co's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was HK$-109.2 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-97.8 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
BioDlink International Co's annualizedROC % for the quarter that ended in Dec. 2025 was -18.88%.
BioDlink International Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -28.76%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
BioDlink International Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -3.28%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioDlink International Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioDlink International Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioDlink International Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BioDlink International Co's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-97.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioDlink International Co (HKSE:01875) has a EBIT of HK$-97.8 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioDlink International Co.
Is BioDlink International Co's EBIT too high?
BioDlink International Co's current EBIT is HK$-97.8 Mil. Overall, BioDlink International Co has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioDlink International Co's EBIT compare to VRTX and REGN?
BioDlink International Co's EBIT of HK$-97.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioDlink International Co. BioDlink International Co's current EBIT is HK$-97.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioDlink International Co stock overvalued right now?
Based on GuruFocus' analysis, BioDlink International Co (HKSE:01875) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.47, compared to a current price of HK$4.02 — trading 173.5% above its estimated fair value. The current EBIT is HK$-97.8 Mil. BioDlink International Co's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For BioDlink International Co (HKSE:01875), the current EBIT is HK$-97.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioDlink International Co (HKSE:01875) Overvalued in 2026?
Based on GuruFocus' analysis, BioDlink International Co stock appears to be overvalued.
The current stock price of HK$4.02 is trading 173.5% above its estimated GF Value™ of HK$1.47.
GuruFocus considers BioDlink International Co to be Significantly Overvalued.
Key valuation signals for HKSE:01875:
EBIT: HK$-97.8 Mil
GF Value™: HK$1.47 vs. price of HK$4.02 (173.5% above fair value)
No single metric tells the full story. See the HKSE:01875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioDlink International Co Ltd is an investment holding company. The Company is mainly engaged in research and development (R&D), manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO) business and license-out of self-developed biological drugs. The company has presence in Mainland China, and Others. The company's services includes ADC R&D Service Platform, Chemical based conjugation process development, Developability assessment for drug product, Drug substance analysis, Antibody Manufacturing, Drug product analysis, etc.
64GF Score
Get the complete analysis for HKSE:01875
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01875 has been successfully added to your 
